Tivanisiran
Dry Eye Disease
Phase 2/3Active
Key Facts
About Sylentis
Sylentis is a clinical-stage biotechnology company pioneering RNAi-based therapies for ocular diseases. The company leverages its proprietary SirFinder™ AI-driven platform to design highly specific siRNA compounds, with a pipeline led by tivanisiran for dry eye disease and SYL1801 for age-related macular degeneration (AMD). As a subsidiary of PharmaMar, Sylentis operates with a dual business model, advancing its own therapeutic pipeline while also offering CDMO and partnership services for external RNAi drug development.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| BRM421 | BRIM Biotechnology | Phase 3 |